Abstract
Prion diseases are infectious and fatal neurodegenerative disorders of man and animals which are characterized by spongiform degeneration in the central nervous system. In human diseases, the manifestation can be sporadic, familial or acquired by infection. Prion disorders are caused by the accumulation of an aberrantly folded isoform of the cellular prion protein (PrPc), commonly named PrPSc. Although prion diseases are usually rare, they have the potential to be transferred within and also between species by infection processes, giving then raise even to epidemic scenarios. As pathology is obviously restricted to the central nervous system pre-mortem diagnosis is usually hard to achieve. Promising approaches towards the development of therapeutic and even prophylactic anti-prion regimens were recently made. However, only a profound knowledge of the infectious agent and its replication strategy enables the design of effective anti-prion strategies. Cell culture models were highly instrumental in uncovering fundamental aspects of prion propagation. In this chapter, the cellular and molecular biology of prion proteins in general is discussed and prophylactic and therapeutic concepts derived thereof are introduced. In particular, emphasis is put on strategies targeting PrPc which is absolutely needed as substrate for prion conversion, and on intrinsic cellular clearance mechanisms for prions.
Keywords: Prion diseases, prion protein, prion clearance, prion therapy, anti-prion drugs
Infectious Disorders - Drug Targets
Title: Therapy in Prion Diseases: From Molecular and Cellular Biology to Therapeutic Targets
Volume: 9 Issue: 1
Author(s): Carmen Krammer, Ina Vorberg, Hermann M. Schatzl and Sabine Gilch
Affiliation:
Keywords: Prion diseases, prion protein, prion clearance, prion therapy, anti-prion drugs
Abstract: Prion diseases are infectious and fatal neurodegenerative disorders of man and animals which are characterized by spongiform degeneration in the central nervous system. In human diseases, the manifestation can be sporadic, familial or acquired by infection. Prion disorders are caused by the accumulation of an aberrantly folded isoform of the cellular prion protein (PrPc), commonly named PrPSc. Although prion diseases are usually rare, they have the potential to be transferred within and also between species by infection processes, giving then raise even to epidemic scenarios. As pathology is obviously restricted to the central nervous system pre-mortem diagnosis is usually hard to achieve. Promising approaches towards the development of therapeutic and even prophylactic anti-prion regimens were recently made. However, only a profound knowledge of the infectious agent and its replication strategy enables the design of effective anti-prion strategies. Cell culture models were highly instrumental in uncovering fundamental aspects of prion propagation. In this chapter, the cellular and molecular biology of prion proteins in general is discussed and prophylactic and therapeutic concepts derived thereof are introduced. In particular, emphasis is put on strategies targeting PrPc which is absolutely needed as substrate for prion conversion, and on intrinsic cellular clearance mechanisms for prions.
Export Options
About this article
Cite this article as:
Krammer Carmen, Vorberg Ina, Schatzl M. Hermann and Gilch Sabine, Therapy in Prion Diseases: From Molecular and Cellular Biology to Therapeutic Targets, Infectious Disorders - Drug Targets 2009; 9 (1) . https://dx.doi.org/10.2174/1871526510909010003
DOI https://dx.doi.org/10.2174/1871526510909010003 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Impact and Therapeutic Potential of PPARs in Alzheimers Disease
Current Neuropharmacology Amyloid β Oligomers Decrease Hippocampal Spontaneous Network Activity in an Age-Dependent Manner
Current Alzheimer Research Outcomes of Perilla Seed Oil as an Additional Neuroprotective Therapy in Patients with Mild to Moderate Dementia: A Randomized Control Trial
Current Alzheimer Research Does Human Alpha-Synuclein Behave Like Prions?
CNS & Neurological Disorders - Drug Targets Docking Studies for Multi-Target Drugs
Current Drug Targets 6-hydroxydopamine Lesion of the Mesolimbic Dopamine System Alters Morphine-Induced Conditioned Reinforcement
Current Psychopharmacology Up-Regulation of Hypoxia-Inducible Factor (HIF)-1α and HIF-Target Genes in Cortical Neurons by the Novel Multifunctional Iron Chelator Anti-Alzheimer Drug, M30
Current Alzheimer Research Novel S-Nitrosothiols Have Potential Therapeutic Uses for Cystic Fibrosis
Current Pharmaceutical Design Ion Channels on Microglia: Therapeutic Targets for Neuroprotection
CNS & Neurological Disorders - Drug Targets Locus (Coeruleus) Minoris Resistentiae in Pathogenesis of Alzheimer’s Disease
Current Alzheimer Research Influence of Essential Trace Minerals and Micronutrient Insufficiencies on Harmful Metal Overload in a Mongolian Patient with Multiple Sclerosis
Current Aging Science Enhanced Tolerance against Early and Late Apoptotic Oxidative Stress in Mammalian Neurons through Nicotinamidase and Sirtuin Mediated Pathways
Current Neurovascular Research Preface
Current Topics in Medicinal Chemistry Heat Shock Proteins and Proteasome Function in Neurodegeneration
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Breakdown of Blood-Brain and Blood-Spinal Cord Barriers During Acute Methamphetamine Intoxication: Role of Brain Temperature
CNS & Neurological Disorders - Drug Targets Role of microRNAs on Blood Brain Barrier Dysfunction in Vascular Cognitive Impairment
Current Drug Delivery PPARs in Neurodegenerative and Neuroinflammatory Pathways
Current Alzheimer Research Effects of Nanosuspension Formulations on Transport, Pharmacokinetics, In Vivo Targeting and Efficacy for Poorly Water-soluble Drugs
Current Pharmaceutical Design <i>In silico</i> Screening of Pyridoxine Carbamates for Anti-Alzheimer’s Activities
Central Nervous System Agents in Medicinal Chemistry Screening of Natural Compounds Against SOD1 as a Therapeutic Target for Amyotrophic Lateral Sclerosis
Letters in Drug Design & Discovery